News

Rexahn has announced that it has completed its registered direct offering of common stock and warrants. Rodman & Renshaw acted as the exclusive placement agent for this transaction.

China Biologic Products has entered into a securities purchase agreement with certain accredited investors led by Essence International Investment. As per the deal, the company will issue 3.8%

Seattle Genetics has reported data from a phase-I clinical trial of SGN-35 administered to patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. Data highlights include longer median

Highlights of the Quarter: The second quarter of 2009 marked a turning point for DiagnoCure’s two commercialized tests, PCA3 for prostate cancer and Previstage GCC for colorectal cancer.

MDRNA has announced in-vivo data from a bladder cancer model demonstrating effective localized delivery of a UsiRNA to a solid tumor, thus further expanding the delivery capabilities of

Sinovac has announced that it has initiated the production of a vaccine against influenza A (H1N1) virus. The virus seed was received from US CDC, and was delivered

Sanofi-Aventis has announced that Sanofi-Aventis Deutschland has purchased the Diabel manufacturing plant in Frankfurt-Hochst, Germany, from Pfizer. Sanofi-Aventis is exercising its step in the right direction, regarding a

Seattle Genetics has reported multiple objective responses at well-tolerated doses from a phase-I clinical trial of lintuzumab (SGN-33) in patients with acute myeloid leukemia (AML). Lintuzumab is a

Merz Pharmaceuticals has announced results from two randomized, active controlled clinical trials in patients with blepharospasm and cervical dystonia. The results were presented at the Movement Disorder Society